A library of 5000 compounds was tested on SKBR3 cells (breast cancer cell line with c-Myc overexpression), and about 1% of compounds were identified as clean positive hits, including known c-Myc pathway inhibitors, and nitazoxanide, a widely used antiprotozoan drug with few side effects. Here, MYC is linked to breast carcinoma.